Over the years, the popularity of oncotarget has been on an upward trajectory. It is important to note that the journal publishes on a weekly basis. The access to the journal is open to all who are interested. After its establishment, the journal has been publishing various works based on oncology. The journal has been playing a very significant role in the furtherance of science and research. There are various reasons why the popularity of the journal has been rising. First and foremost, the journal has been in the forefront providing insightful peer review.The journal has also been consistent in publishing constructive and punctual peer review and hence making it a leader in cancer field. It is important to note that the journal was founded in the year 2015. Ever since it was founded, oncotarget has been accepting papers on diverse topics.
For instance, the journal has been open to accepting papers dealing with neurosciences. The journal is also known for accepting papers which are based on metabolism and cardiology. The main aim of oncotarget is to disseminate scientific results as fast as possible.The journal has also succeeded in giving certain works a lot of prominence. When a certain research has been given huge prominence, it becomes easier for it to attract financing. The journal has also succeeded in enhancing the impact that research has by providing a good platform for an insightful review.
Through the journal, it has now become possible for researchers to share their discoveries within a short period of time. In the past, there have been major borders between the various specialties.However, oncotarget has played a major role in ensuring that such borders do not exist anymore. The continued collaboration in the scientific field has made it possible for faster discoveries to be made. The leadership of the journal has played a very significant role with regards to helping the promotion of science. For instance, all scientists have an opportunity to publish their work for all to see. The ultimate goal of the journal is to have a world that is not affected by major illnesses.
Eric Lefkofsky is the founder and CEO of Groupon which is an American global online marketplace, where people connect with merchants providing different goods and services. Eric Lefkofsky is based in Chicago and being philanthropic; he has contributed millions of dollars to assist in cancer researching. He has also planned to invest more targeting to get a cancer cure, and in this case, he started Tempus. Tempus is a heath-tech startup that is building infrastructure that will help cure cancer in a modernized way.
On dropping his role as a CEO at Groupon, Eric Lefkofsky began working on Tempus Health Inc. as the president. COO Rich Williams who was a former CEO replaced him in November 2015. According to Tempus’ website, doctors, and other medical practitioners are being assisted in making immediate, personalized as well as data-driven decisions when treating patients. They are doing this by examining patient’s genetic codes from molecular therapies provided, and it helps them understand patient’s tumor in a better manner as well.
Tempus is using modernized infrastructure to collect and examine the genomic data of a patient which helps the doctors to give personalized medicines to patients. The data that Tempus is collecting about a patient is what the physicians use to come up with an effective personalized plan to treat each patient. So far they are helping patients suffering from lung, breast as well as pancreatic cancer and expects to be able to cater for more types of cancer in time.
Eric Lefkofsky (www.lefkofsky.com/) together with his wife has been contributing towards research on cancer cause through the Lefkofsky Family Foundation. Through the foundation, they donated $1 million towards Robert H. Lurie Comprehensive Cancer Center of Northwestern University, $500,000 towards research on gastric cancer at Stanford University, $1.2 million for a cancer research in the University of Michigan and $250,000 towards research on a medicine regarding breast cancer.
Apart from giving donations, Lefkofsky is a trustee at Lurie Children’s Hospital based in Chicago. He also joined The Giving Pledge in 2013 and promised to give half of their wealth towards philanthropic activities. In his blog post relating to Tempus (though he didn’t mention it), he said that having big data and artificial intelligence is good motive to take the society to the next level. He added that the best infrastructure is certainly in the healthcare and large databases of molecular data are available to ease the treatment plan. He talked and described the trend of applications that are scientifically applied in the health sector.
Lefkofsky is a renowned entrepreneur in Chicago and has founded several other companies including Echo Global Logistics, Mediaocean as well as InnerWorkings. Visit his page on Facebook.